Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
about
The drug-drug interaction between proton pump inhibitors and clopidogrelPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsThe prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysisHigh residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistancePlatelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysisPharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood.Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary SyndromeThe impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC studyAssociation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyPharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic eventsHostility and platelet reactivity in individuals without a history of cardiovascular disease events.Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.Clinical importance of aspirin and clopidogrel resistanceNew Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications.Drug-drug interaction between clopidogrel and the proton pump inhibitors.Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study.In Vitro Assessment of Cytochrome P450 2C19 Potential of NaoxintongAssociation of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting.Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary interventionImpact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome.CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.Thromboelastography for monitoring platelet function in unruptured intracranial aneurysm patients undergoing stent placement.Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastographyComparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.Aspirin and clopidogrel response variability: review of the published literatureAssociations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.Interaction between statins and clopidogrel: is there anything clinically relevant?Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoEffect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label studyRecent developments in clopidogrel pharmacology and their relation to clinical outcomes.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
P2860
Q24653812-C57CB260-7258-4C9D-B673-C029C0266D96Q26775125-9AE9CEEA-D2D3-48E7-81D1-C79C7034FE88Q26824694-C961D30E-6D3E-487D-A804-7303B018989FQ26824850-4687BC06-B669-4397-BFDF-2557B6093FC2Q27010236-A0F712F7-FC52-4663-B2CA-6BAEBCC6ED7CQ27022443-3BBE99B1-996A-4641-B2B8-81293DF08D6FQ30450312-CE5C819A-BA2B-4390-B768-6691A0FD6960Q30498026-9BEC4526-DB62-47D0-99E3-55B3D1F26C43Q33760816-39CE4BDA-EA4C-4BEB-BE2F-36154EBA4EECQ33893919-CF1DAB03-A823-4270-B754-556678E674C4Q34019082-59990789-9201-4787-8706-F3519DE3A61BQ34019342-5BDB5C23-0800-4565-85A3-5B748A61B26DQ34111144-55CEE3AE-93CB-4AA4-85A4-26FEA2EBE46EQ34211191-7019E817-F5DD-43ED-B12E-AA68968D254DQ34382431-5AC43EC7-FE57-439F-B690-AA783C907CBBQ34390050-899AA896-8D17-4B40-AEF7-5341C15EEE79Q34532327-10EC2C48-7272-4A21-820C-886DC11FD7B5Q34983154-E80181BF-AB1A-46AC-806B-DC65E1C4F610Q35373683-9DBF4717-C351-470D-8997-C22059D3DA3DQ35707491-A2029BE9-5C11-4EE9-8D21-B6DD640C7556Q35796575-D4BAABB5-93E0-4348-AB32-23610475B2F6Q35921906-F7B8FA6E-8ECA-46BC-882D-3752BFC4A56FQ35959359-28C9DFC6-9B8F-4046-BE35-9B257EDC2394Q36078210-287696ED-9C64-4460-BF09-6476718F1341Q36477309-AB344D94-3C4B-454F-A09E-A12EDA086F6DQ36589808-5F13758E-6918-4CCB-8678-1DC113B29631Q36720281-629CC2E8-F4DA-4733-BDC3-A91A68120BD6Q36800844-E0905383-9A7F-4E11-85A1-49C9FCBDF677Q36804776-1ADCBAF0-1C8C-4298-A1AB-AFFA6A2DA9D1Q36932221-63BA0F65-65DE-401A-BD4F-89F50C01C37DQ37067222-5736525A-DA95-4C70-8FD7-2A996030443CQ37203987-26FC71CC-3BBF-4241-868C-8D7630F4F033Q37234094-3B6489A7-AA6B-4F45-88DC-1D9731975A32Q37291972-D5FA2C41-2B12-4E7E-8BCE-0C213ED51139Q37339517-56A28E61-F2E6-40A7-8434-BA23837BD752Q37378896-2C345947-A75C-439A-9C3A-BFF98F570FE5Q37396871-FE200A2C-E75E-449D-9460-1FC84213A5E1Q37540088-B02B4FC6-8530-4119-8E8A-621D1531387EQ37550156-E7DB273B-2450-43FB-9D83-351EB4C7637EQ37552005-48AE2050-C104-4FE2-AE4C-76E5826D14E3
P2860
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Increased risk in patients wit ...... antiplatelet therapy adequate?
@ast
Increased risk in patients wit ...... antiplatelet therapy adequate?
@en
Increased risk in patients wit ...... antiplatelet therapy adequate?
@nl
type
label
Increased risk in patients wit ...... antiplatelet therapy adequate?
@ast
Increased risk in patients wit ...... antiplatelet therapy adequate?
@en
Increased risk in patients wit ...... antiplatelet therapy adequate?
@nl
prefLabel
Increased risk in patients wit ...... antiplatelet therapy adequate?
@ast
Increased risk in patients wit ...... antiplatelet therapy adequate?
@en
Increased risk in patients wit ...... antiplatelet therapy adequate?
@nl
P2093
P3181
P1476
Increased risk in patients wit ...... antiplatelet therapy adequate?
@en
P2093
Ashwani K Bassi
Joseph DiChiara
Kevin P Bliden
Paul A Gurbel
Srivasavi K Chaganti
Udaya S Tantry
P304
P3181
P356
10.1016/J.JACC.2006.10.050
P407
P577
2007-02-13T00:00:00Z